[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:parp1-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"PARP1 Gene",2,1,[8,16],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07590934","Phase Ib\u002FII Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:15:56.561131Z","2026-05-29T15:36:40.200576Z",{"nct_id":17,"title":18,"phases":19,"status":21,"updated_at":22,"content_modified":23},"NCT07673341","[18F]FTT Positron Emission Tomography\u002FComputed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma",[20],"Phase 2","NOT_YET_RECRUITING","2026-08-26T02:19:08.862440Z","2026-07-05T03:45:20.432594Z"]